Get 50% OFF This Summer!

Advertisement
logo

Sai Life Sciences

SAILIFE
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Sai Life Sciences Share price and Fundamental Analysis

View All Details
View All Details
Sai Life Sciences Limited was originally incorporated as Sai Dru Syn Laboratories Limited' as a Public Limited Company, dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. The Company received the Certificate of Commencement of Business from Registrar of Companies, Andhra Pradesh on February 17, 1999. Subsequently, the Company name was changed from Sai Dru Syn Laboratories Limited' to Sai Life Sciences Limited' dated December 16, 2003.
Company Incorporation1999
ChairmanRanga Raju Kanumuri
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
14,867
PE Ratio
107.76
Industry P/E
35.21
PEG Ratio
0
ROE
11.84%
ROCE
12.38%
ROA
0%
Total Debt (Cr)
0
Debt to Equity
0.95
Dividend Yield
0%
EPS
6.62
Book Value & P/B
94.15 x 7.58
Face Value
1
Outstanding Shares(Cr)
20.84
Current Ratio
3.26
EV to Sales
10.09

Included In

+More

Stock Returns

1 Week-0.51%
1 Month-7.39%
6 Months-6.62%
1 Year-6.62%
3 Years-6.62%
5 Years-6.62%

CAGR

1 Year CAGR

Revenue Growth

+20.38%

Net Profit Growth

+729%

Operating Profit Growth

+63.08%

Dividend Growth

-100%

Stock Returns CAGR

-6.62%
no_data

No Stocks

Smart Score

1.4
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 35.17%

FIIs : 12.36%

DIIs : 13.26%

Public : 39.21%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 2.67% of holding in March 2025 Qtr
FII Shareholding Increased by 4.72% to 12.36% in March 2025 Qtr
DII Shareholding Increased by 7.9% to 13.26% in March 2025 Qtr
Promoter Shareholding Decreased by 0.07% to 35.17% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Sai Life Sciences Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Sai Life Sciences Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Sai Life Sciences Limited was originally incorporated as Sai Dru Syn Laboratories Limited' as a Public Limited Company, dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. The Company received the Certificate of Commencement of Business from Registrar of Companies, Andhra Pradesh on February 17, 1999. Subsequently, the Company name was changed from Sai Dru Syn Laboratories Limited' to Sai Life Sciences Limited' dated December 16, 2003.

Thereafter, the name of the Company was changed from Sai Life Sciences Limited' to Sai Advantium Pharma Limited' dated August 30, 2006 issued by the Registrar of Companies, Andhra Pradesh. Subsequently, the Company name was changed from Sai Advantium Pharma Limited' to Sai Life Sciences Limited' and a fresh Certificate of Incorporation dated May 28, 2012 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.

The Company is an innovator-focused contract research, development, and manufacturing organization (CRDMO). The Company provide end-to-end services across the drug discovery, development and manufacturing value chain, for small molecule NCE to global pharmaceutical innovators companies and biotechnology firms. It possess both (a) discovery / contract research and (b) CMC / CDMO capabilities.

Through the Scheme of Amalgamation, Prasad Drugs Limited was merged into the Company in 2004. The Company acquired Merrifield Pharma Private Limited in 2006. Later, the Company opened new areas of biology facility in Watertown (Greater Boston, MA) U.S.A. for innovative and creative small-molecule drugs in 2019. It launched Sai Nxt, an initiative to transform the organization into a new generation CDMO in 2020. It further added cellular analysis platforms at its discovery biology facility in Cambridge, Massachusetts, USA.

In 2021, the Company opened a new discovery biology facility at Unit II Plant in Hyderabad. In 2022, it opened the first set of new disconvery chemistry labs at Unit III Plant, Hyderabad.

In 2023, the Company opened high potency API manufacturing block at Unit IV Bidar Facility and has started API developability & formulations (D&F) capabilities at Unit II Hyderabad in 2024.

The Company is proposing to raise money from public through IPO by issue and allotment of 61,573,120 Equity Shares through Offer for Sale and a Fresh Issue aggregating to Rs 800 Crores Equity Shares.

Sai Life Sciences Share Price

Sai Life Sciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Sai Life Sciences Market Cap

Market capitalization of Sai Life Sciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Sai Life Sciences is valued compared to its competitors.

Sai Life Sciences PE Ratio

Sai Life Sciences PE ratio helps investors understand what is the market value of each stock compared to Sai Life Sciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Sai Life Sciences PEG Ratio

The PEG ratio of Sai Life Sciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Sai Life Sciences ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Sai Life Sciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Sai Life Sciences ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Sai Life Sciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Sai Life Sciences Total Debt

Total debt of Sai Life Sciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Sai Life Sciences Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Sai Life Sciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Sai Life Sciences CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Sai Life Sciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Sai Life Sciences Technical Analysis

Technical analysis of Sai Life Sciences helps investors get an insight into when they can enter or exit the stock. Key components of Sai Life Sciences Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Sai Life Sciences shares often struggle to rise above due to selling pressure.

Sai Life Sciences Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Sai Life Sciences ’s financial health and profitability.

Sai Life Sciences Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Sai Life Sciences Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Sai Life Sciences Financials

The financials of Sai Life Sciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Sai Life Sciences Profit and Loss Statements

The profit and loss statement of Sai Life Sciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Sai Life Sciences .

Sai Life Sciences Balance Sheet

The balance sheet presents a snapshot of Sai Life Sciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Sai Life Sciences Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App